Renaissance Technologies
CBMG

Renaissance Technologies’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Renaissance Technologies’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-24,000
Closed -$359K – 3823
2020
Q2 		$359K Buy
+24,000
New +$343K ﹤0.01% 2984
2015
Q2 		– Sell
-8,200
Closed -$258K – 3453
2015
Q1 		$258K Buy
+8,200
New +$222K ﹤0.01% 2807

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Renaissance Technologies's CBMG Position: Q3 2020 in Review

Renaissance Technologies sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2020, closing a stake of 24,000 shares — an estimated $359K sold.

Renaissance Technologies first reported a position in CBMG in Q1 2015 and held it in 2 quarters. The position peaked at $359K in Q2 2020. 73 funds tracked by Wall St. Rank hold CBMG as of Q3 2020.

  • Renaissance Technologies reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2020 after selling out during the quarter.
  • Renaissance Technologies sold 24,000 Cellular Biomedicine Group, Inc. shares in Q3 2020, an estimated $359K.
  • Renaissance Technologies first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 2 quarters.
  • Renaissance Technologies's Cellular Biomedicine Group, Inc. position peaked at $359K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2020.

Based on Renaissance Technologies's 13F filing for Q3 2020, filed 13 Nov 2020.